FibroGen FGEN Stock
FibroGen Price Chart
FibroGen FGEN Financial and Trading Overview
| FibroGen stock price | 0.33 USD |
| Previous Close | 0.6 USD |
| Open | 0.6 USD |
| Bid | 0.42 USD x 200 |
| Ask | 0.72 USD x 200 |
| Day's Range | 0.55 - 0.6 USD |
| 52 Week Range | 0.18 - 2.93 USD |
| Volume | 684.88K USD |
| Avg. Volume | 1.41M USD |
| Market Cap | 58.39M USD |
| Beta (5Y Monthly) | 0.726 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.53 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10 USD |
FGEN Valuation Measures
| Enterprise Value | 103.85M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.8397102 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.33590773 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 0.597 |
| Enterprise Value/EBITDA | -0.626 |
Trading Information
FibroGen Stock Price History
| Beta (5Y Monthly) | 0.726 |
| 52-Week Change | -24.11% |
| S&P500 52-Week Change | 22.67% |
| 52 Week High | 2.93 USD |
| 52 Week Low | 0.18 USD |
| 50-Day Moving Average | 0.43 USD |
| 200-Day Moving Average | 0.72 USD |
FGEN Share Statistics
| Avg. Volume (3 month) | 1.41M USD |
| Avg. Daily Volume (10-Days) | 1.72M USD |
| Shares Outstanding | 100.77M |
| Float | 90.52M |
| Short Ratio | 3.27 |
| % Held by Insiders | 0.84% |
| % Held by Institutions | 55.03% |
| Shares Short | 4.32M |
| Short % of Float | 5.07% |
| Short % of Shares Outstanding | 4.30% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | -96.83% |
| Operating Margin (ttm) | -21.56% |
| Gross Margin | -34.39% |
| EBITDA Margin | -95.40% |
Management Effectiveness
| Return on Assets (ttm) | -26.54% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 173.82M USD |
| Revenue Per Share (ttm) | 1.76 USD |
| Quarterly Revenue Growth (yoy) | 14.29% |
| Gross Profit (ttm) | -59789000 USD |
| EBITDA | -165835008 USD |
| Net Income Avi to Common (ttm) | -168324000 USD |
| Diluted EPS (ttm) | -1.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 140.71M USD |
| Total Cash Per Share (mrq) | 1.4 USD |
| Total Debt (mrq) | 163.78M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.41 |
| Book Value Per Share (mrq) | -2.067 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -202016000 USD |
| Levered Free Cash Flow (ttm) | -121833376 USD |
Profile of FibroGen
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 409 Illinois Street |
| ZIP | 94158 |
| Phone | 415 978 1200 |
| Website | https://www.fibrogen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 486 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Q&A For FibroGen Stock
What is a current FGEN stock price?
FibroGen FGEN stock price today per share is 0.33 USD.
How to purchase FibroGen stock?
You can buy FGEN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for FibroGen?
The stock symbol or ticker of FibroGen is FGEN.
Which industry does the FibroGen company belong to?
The FibroGen industry is Biotechnology.
How many shares does FibroGen have in circulation?
The max supply of FibroGen shares is 102.94M.
What is FibroGen Price to Earnings Ratio (PE Ratio)?
FibroGen PE Ratio is now.
What was FibroGen earnings per share over the trailing 12 months (TTM)?
FibroGen EPS is -1.53 USD over the trailing 12 months.
Which sector does the FibroGen company belong to?
The FibroGen sector is Healthcare.
FibroGen FGEN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4527.84 USD — |
+1.29
|
— — | 4484.64 USD — | 4546.65 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2076.39 USD — |
+0.55
|
— — | 2051.38 USD — | 2085.49 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21258.23 USD — |
-0.1
|
— — | 20967.6 USD — | 21382.13 USD — | — - | — — |
| NASDAQ Philippines Utilities Lg NQPH7000LMPHPT | 1112.33 PHP 20 USD |
<0.01
|
— — | 1112.33 PHP 20 USD | 1112.33 PHP 20 USD | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2765.32 USD — |
+0.46
|
— — | 2735.39 USD — | 2775.41 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}